{
  "ticker": "RARE",
  "company_name": "Ultragenyx Pharmaceutical Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02991144",
      "title": "Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Ornithine Transcarbamylase (OTC) Deficiency",
      "start_date": "2017-07-31",
      "completion_date": "2021-12-16",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT04990388",
      "title": "Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Glycogen Storage Disease Type III",
      "start_date": "2021-10-18",
      "completion_date": "2023-03-20",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT02230566",
      "title": "A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "MPS 7, Sly Syndrome, Mucopolysaccharidosis, MPS VII",
      "start_date": "2014-12",
      "completion_date": "2016-05",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT06340685",
      "title": "Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Pyruvate Dehydrogenase Complex Deficiency",
      "start_date": "2024-07-11",
      "completion_date": "2027-06-30",
      "enrollment": 0,
      "sponsor": "Jirair Krikor Bedoyan"
    },
    {
      "nct_id": "NCT03517085",
      "title": "Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa)",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "GSD1",
      "start_date": "2018-05-18",
      "completion_date": "2021-11-02",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT02716246",
      "title": "Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH",
      "status": "RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III",
      "start_date": "2016-04-25",
      "completion_date": "2027-07",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT02214160",
      "title": "Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency, Carnitine-acylcarnitine Translocase (CACT) Deficiency",
      "start_date": "2014-12-09",
      "completion_date": "2020-12-03",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT03581591",
      "title": "Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic",
      "start_date": "2018-01-31",
      "completion_date": "2019-12-06",
      "enrollment": 0,
      "sponsor": "Redwood Dermatology Sciences"
    },
    {
      "nct_id": "NCT05368038",
      "title": "ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "",
      "condition": "Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2, Cerebrotendinous Xanthomatosis, Fabry Disease, GM1 Gangliosidosis, Gaucher Disease, Lysosomal Acid Lipase Deficiency, Metachromatic Leukodystrophy, Mucopolysaccharidosis II, Mucopolysaccharidosis III-B, Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidosis VII, Niemann-Pick Disease, Type C",
      "start_date": "2021-05-10",
      "completion_date": "2029-08-31",
      "enrollment": 0,
      "sponsor": "Albert Einstein College of Medicine"
    },
    {
      "nct_id": "NCT04812106",
      "title": "Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program",
      "status": "TERMINATED",
      "phase": "",
      "condition": "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)",
      "start_date": "2022-07-25",
      "completion_date": "2022-10-27",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1, PHASE2": 7,
      "PHASE3": 7,
      "PHASE1": 1,
      "PHASE2, PHASE3": 1,
      "PHASE2": 16,
      "": 16,
      "EARLY_PHASE1": 2
    },
    "by_status": {
      "COMPLETED": 24,
      "TERMINATED": 6,
      "RECRUITING": 4,
      "ENROLLING_BY_INVITATION": 3,
      "NO_LONGER_AVAILABLE": 3,
      "ACTIVE_NOT_RECRUITING": 5,
      "UNKNOWN": 3,
      "WITHDRAWN": 1,
      "SUSPENDED": 1
    },
    "active_trials": 12,
    "completed_trials": 24,
    "conditions": [
      "ALS",
      "Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2, Cerebrotendinous Xanthomatosis, Fabry Disease, GM1 Gangliosidosis, Gaucher Disease, Lysosomal Acid Lipase Deficiency, Metachromatic Leukodystrophy, Mucopolysaccharidosis II, Mucopolysaccharidosis III-B, Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidosis VII, Niemann-Pick Disease, Type C",
      "Adult Polyglucosan Body Disease, Glycogen Brancher Enzyme Deficiency, Glycogen Storage Disease Type IV",
      "Angelman Syndrome",
      "Angelman Syndrome, Prader-Willi Syndrome",
      "Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency, Carnitine-acylcarnitine Translocase (CACT) Deficiency",
      "Chronic-kidney Disease Stage 5D on Stable Hemodialysis",
      "Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome",
      "GNE Myopathy, Hereditary Inclusion Body Myopathy",
      "GNE Myopathy, Hereditary Inclusion Body Myopathy (HIBM)",
      "GSD1",
      "Glucose Transporter 1 Deficiency Syndrome",
      "Glucose Transporter Type 1 Deficiency Syndrome",
      "Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)",
      "Glycogen Storage Disease Type I",
      "Glycogen Storage Disease Type IA",
      "Glycogen Storage Disease Type III",
      "Glycogen Storage Disease Type Ia",
      "Glycogen Storage Disease Type V",
      "Hemophilia B",
      "Hereditary Inclusion Body Myopathy, GNE Myopathy, Nonaka Disease, Quadriceps Sparing Myopathy (QSM), Distal Myopathy With Rimmed Vacuoles (DMRV)",
      "Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic",
      "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)",
      "MPS 7, Sly Syndrome, Mucopolysaccharidosis, MPS VII",
      "MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III",
      "Medium-chain Acyl-CoA Dehydrogenase Deficiency",
      "Mucopolysaccharidoses, Carotid Disease, Cardiac Disease, Inflammation",
      "Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A",
      "Mucopolysaccharidosis Type 7",
      "Ornithine Transcarbamylase (OTC) Deficiency",
      "Ornithine Transcarbamylase Deficiency, Wilson Disease, Glycogen Storage Disease Type IA",
      "Osteogenesis Imperfecta",
      "Pyruvate Dehydrogenase Complex Deficiency",
      "Rett Syndrome",
      "Sly Syndrome, MPS VII, Mucopolysaccharidosis, Mucopolysaccharidosis VII",
      "Tarui Disease, Debrancher Deficiency, GYG1 DEFICIENCY",
      "Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2), Mitochondrial Trifunctional Protein Deficiency, Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency, Glycogen Storage Disorders, Pyruvate Carboxylase Deficiency Disease, ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY of, Barth Syndrome",
      "Wilson Disease"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:33:35.918497",
    "search_query": "Ultragenyx Pharmaceutical Inc.",
    "url": "https://clinicaltrials.gov/search?term=Ultragenyx+Pharmaceutical+Inc."
  }
}